Avalo Therapeutics (AVTX) jumps as Phase 2 LOTUS topline results and $375M financing reshape outlook

Avalo Therapeutics, Inc. (AVTX) is up 34.4% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears driven by newly disclosed positive Phase 2 clinical data for abdakibart (AVTX-009) in hidradenitis suppurativa, which the company characterized as meeting its primary endpoint with statistically significant results. Investors also reacted to the company’s large, newly priced equity financing, which can be interpreted as both near-term dilution and a stronger cash runway to fund the next stage of development.

Details:

A Form 8-K dated May 5, 2026 disclosed positive topline Phase 2 LOTUS results for abdakibart in moderate-to-severe hidradenitis suppurativa.

The company said the LOTUS study met its primary endpoint (HiSCR75 at Week 16) for both doses studied and showed benefits on key secondary endpoints, with a safety profile described as favorable.

The company stated it plans to advance abdakibart into a registrational Phase 3 program following these results.

Avalo also announced the pricing of an underwritten public offering targeting about $375 million in gross proceeds at $17.75 per share (and pre-funded warrants), with closing expected May 7, 2026 and proceeds intended to support abdakibart development and general corporate purposes.

Sources:

SEC, Avalo Therapeutics Investor Relations, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$AVTX Insider Trading Activity

$AVTX insiders have traded $AVTX stock on the open market 11 times in the past 6 months. Of those trades, 0 have been purchases and 11 have been sales.

Here’s a breakdown of recent trading of $AVTX stock by insiders over the last 6 months:

MITTIE DOYLE (Chief Medical Officer) has made 0 purchases and 3 sales selling 30,141 shares for an estimated $493,979.
CHRISTOPHER RYAN SULLIVAN (Chief Financial Officer) has made 0 purchases and 6 sales selling 32,874 shares for an estimated $493,182.
JONATHAN GOLDMAN has made 0 purchases and 2 sales selling 11,367 shares for an estimated $162,936.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.

EARLY ACCESS

Receive AVTX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$AVTX Hedge Fund Activity

We have seen 57 institutional investors add shares of $AVTX stock to their portfolio, and 27 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

UBS GROUP AG added 664,164 shares (+139.0%) to their portfolio in Q1 2026, for an estimated $9,915,968
MILLENNIUM MANAGEMENT LLC added 522,548 shares (+380.2%) to their portfolio in Q4 2025, for an estimated $9,489,471
JENNISON ASSOCIATES LLC added 475,625 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,637,350
MARSHALL WACE, LLP added 451,541 shares (+806.2%) to their portfolio in Q4 2025, for an estimated $8,199,984
SOLEUS CAPITAL MANAGEMENT, L.P. added 441,978 shares (+inf%) to their portfolio in Q4 2025, for an estimated $8,026,320
POINT72 ASSET MANAGEMENT, L.P. removed 426,481 shares (-40.5%) from their portfolio in Q4 2025, for an estimated $7,744,894
BALYASNY ASSET MANAGEMENT L.P. removed 378,124 shares (-46.3%) from their portfolio in Q4 2025, for an estimated $6,866,731

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.

$AVTX Analyst Ratings

Wall Street analysts have issued reports on $AVTX in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 05/06/2026
Guggenheim issued a "Buy" rating on 02/02/2026
HC Wainwright & Co. issued a "Buy" rating on 01/15/2026
Mizuho issued a "Outperform" rating on 12/18/2025

To track analyst ratings and price targets for $AVTX, check out Quiver Quantitative's $AVTX forecast page.

$AVTX Price Targets

Multiple analysts have issued price targets for $AVTX recently. We have seen 7 analysts offer price targets for $AVTX in the last 6 months, with a median target of $48.0.

Here are some recent targets:

Julian Harrison from BTIG set a target price of $58.0 on 05/06/2026
Robert Driscoll from Wedbush set a target price of $40.0 on 05/06/2026
Andy Chen from Wolfe Research set a target price of $48.0 on 04/09/2026
Jason Butler from Citizens set a target price of $52.0 on 04/06/2026
Mitchell S. Kapoor from HC Wainwright & Co. set a target price of $40.0 on 03/25/2026
Yatin Suneja from Guggenheim set a target price of $50.0 on 02/02/2026
Joseph Catanzaro from Mizuho set a target price of $39.0 on 12/18/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.